Tardive Dyskinesia: Facts the mental health administrator may not know
- 12 Downloads
Hospitals and other health care organizations are under constant pressure to meet standards which ensure patient progress and welfare. It is their ethical and professional responsibility to do so. Should a hospital fail to meet these standards, legal entanglements will occur.
In general, the health care community makes a sincere attempt to meet its ethical obligations. When a hospital does not, however, it may be that methods and procedures to meet the standard of care are not specified or do not exist.
▪ Tardive dyskinesia is a very real problem that must be resolved soon.
▪ There is a legal mandate which demands hospitals to systematically monitor for behavioral side effects due to neuroleptic medications.
▪ The price for failing to monitor for TD may cost the hospital and physicians millions of dollars.
▪ There is a cost-effective, efficient and reliable manner in which to manage this problem.
The solution calls for a comprehensive dyskinesia monitoring and cvaluation system.
KeywordsTardive Dyskinesia Hospital Administrator Mental Health Field Task Force Report Neuroleptic Medication
Unable to display preview. Download preview PDF.
- 1.Clites v. Iowa, No. 46274 (Iowa District Court for Pottawattamic County, filed August 7, 1980).Clites v. Iowa, 2-04-2-65599 (Iowa Court of Appeals, filed June 29, 1982).Google Scholar
- 2.Faigenbaum v. Cohen, No. 79-904-736-NM (Wayne County Michigan, filed February 14, 1979).Google Scholar
- 3.Headley v. Hanneken is reported as a summary in “Doctor Continues Use of Drug in Spite of Side Effects: Tardive Dyskinesia; S315,000 Recovery as a Result of Verdict and Settlement.”Verdict, 6, 61–62, 1984.Google Scholar
- 4.Hedin v.U.S.A., No. 5-83 CIV 3 (United States District Court, District of Minnesota, Fifth Division, filed September 4, 1984).Google Scholar
- 5.Lesser v. Farbe, Synopsis reported in: Patterson, J.D. & Robinson, R.E. (Eds.),Drugs in Litigations: Damage Awards Involving Prescription Drugs (2nd Ed). Indianapolis: Allen Smith Co., 1982.Google Scholar
- 6.Collins v. Cushner, id..Google Scholar
- 8.American Psychiatric Association Task Force Report on Late Neurological Effects of Antipsychotic Drugs,Tardive Dyskinesia. Task Force Report 18. Washington D.C.: American Psychiatric Association, 1979.Google Scholar
- 9.R.J. Baldessarini and D. Tarsey, “Tardive Dyskinesia.” In M.A. Kipton, A. Di-Mascio, & K.F. Killam (Eds.),Psychopharmacology: A Generation of Progress, pp. 993–1004, New York, NY: Raven Press, 1978.Google Scholar
- 10.J.E. Kalachnik, et al., “Persistent Tardive Dyskinesia in Randomly Assigned Neuroleptic History Groups: Preliminary Results.”Psychopharmacology Bulletin, in press.Google Scholar
- 11.D.V. Jeste and R.J. Wyatt,Understanding and Treating Tardive Dyskinesia. New York, NY. Guilford Press, 1982. J.E. Kalachnik, “Tardive Dyskinesia,”Minnesota Pharmacist, 37, 6–13, 1983b.Google Scholar
- 16.G.D. Mellinger and M.B. Balter, “Prevalence and Patterns of Use of Psychotropic Drugs: Results from a 1979 National Survey of American Adults.” In G. Tognoni, C. Bellantuono & M. Lader (Eds.),Epidemiological Impact of. Psychotropic Drugs, Amsterdam; Elservier-North Holland, Biomedical Press, 1981. Sandoz Pharmaceuticals.Tardive Dyskinesia: The Key Issue in Psychiatric Practice Today (MEL-283). Aust Hanover, NJ, 1982.Google Scholar
- 18.Nina Schooler et al., Psychopharmacology Branch, National Institute of Mental Health, Rockville, MD.Google Scholar
- 19.George Simpson, Professor of Psychiatry, University of Southern California, Los Angeles, CA. Also Director, USC-MSH Psychopharmacology Service, Metropolitan State Hospital, Norwalk, CA.Google Scholar
- 20.Robert Smith, Chief Behavioral Neurochemistry, Texas Research Institute of Mental Sciences, Houston. Also Research Assistant Professor of Pharmacology, Baylor College of Medicine, Houston, TX.Google Scholar
- 21.Jes Gerlach, Section Hans Hospital, Department H, Rosklide, Denmark.Google Scholar
- 22.R.J. Sprague, Institute of Child Behavior and Development. University of Illinois, Champaign, IL.Google Scholar
- 23.J.E. Kalachnik, State of Minnesota, Cambridge State Hospital, Cambridge, MN.Google Scholar
- 24.David M. Englehardt, Professor of Psychiatry, Department of Psychiatry/psychopharmacology, Downstate Medical Center, SUNY, 450 Clarkson Avenue, Brooklyn, New York, 11203.Google Scholar
- 25.Minnesota facilities: Anoka, Brainird, Cambridge, Fergus Falls, Moose Lake, St. Peter and Willmar; Colorado: Wheatridge; Illinois: McFarland, Meyer, Jacksonville, Lincoln, and Dwight; Kansas: Norton; Michigan: Mt. Pleasant; Virginia: Southeastern.Google Scholar